| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Charles River Laboratories International, Inc.$219.4
-0.3 (-0.14%)
Market Cap
8.65 B
EPS
-2.95
P/E Ratio
-59.62 $
Value Trade
95.16 M
SEC Financials
Q1 2026Dilution Risk
Revenue
995.83 M
Operating CF
41.08 M
Total Assets
7.73 B
Total Liabilities
4.74 B
Equity
2.94 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
198.20 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
925.04 K
52 Week Range
99.80 - 228.88
% held by Insiders
1.13 %
% held by Institutions
121.58 %
Enterprise Value
11.11 B
Total Shares
49.34 M
Short %
9.14 %
Float Shares
48.70 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Charles River Laboratories International, Inc.
63Total events
0Upcoming
13Tier-1 (high impact)
2016 – 2026Coverage
Event history 2
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CRL
Jul 13, 2026Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
Charles River Laboratories has partnered with Arovella Therapeutics to provide GMP Next Generation Sequencing services. This collaboration aims to support Arovella in developing an Invariant Natural Killer T cell therapy platform for cancer treatment. The partnership is expected to accelerate progress towards innovative cancer treatment approaches.
Read more →-CRL
Jun 18, 2026Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
Charles River Laboratories has partnered with Eli Lilly's TuneLab to enhance their AI/ML platform by leveraging Charles River's expertise in nonclinical testing. This collaboration aims to optimize the integration of artificial intelligence and machine learning in drug development processes. The partnership reflects a growing trend in the biopharma industry to utilize advanced technologies for improving research outcomes.
Read more →-CRL
May 11, 2026▼ -5.2%on this news
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
Charles River is enhancing its digital pathology services through the implementation of an AI-powered end-to-end workflow. This advancement aims to streamline processes and improve efficiency in pathology diagnostics. The initiative reflects a growing trend in the biopharma industry towards integrating artificial intelligence in laboratory settings.
Read more →-CRL
Apr 21, 2026Charles River Highlights Effectiveness of VCGs in Toxicology
Charles River Laboratories has released a retrospective analysis demonstrating the effectiveness of virtual control groups (VCGs) in toxicology studies. The analysis showed that VCGs can replace traditional animal models without compromising scientific integrity, achieving 100% concordance in key safety assessments. The initiative aims to enhance study efficiency and reduce animal use in research, supported by ongoing collaborations with regulatory agencies.
Read more →-CRL
Apr 17, 2026Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call
Charles River Laboratories International, Inc. will release its first-quarter 2026 financial results on May 7th, prior to market opening. A conference call is set for the same day at 8:30 a.m. ET to discuss these results. Investors can access a live webcast and a replay through the company's Investor Relations website.
Read more →-CRL
Mar 2, 2026Charles River Laboratories to Present at TD Cowen and Barclays Conferences
Charles River Laboratories announced its participation in two upcoming investor conferences. Management will present an overview of the company's strategic focus, business developments, and recent trends. Live webcasts of the presentations will be available, with replays accessible for at least two weeks. This engagement highlights the company's commitment to transparency and investor relations.
Read more →-CRL
Feb 18, 2026Charles River Laboratories Announces Executive Appointments
Charles River Laboratories has announced the appointment of Glenn G. Coleman as Chief Financial Officer and Kerry Dailey as Chief Legal Officer. These appointments are part of a strategic effort to strengthen the leadership team and enhance operational efficiency. Both executives bring extensive experience in their respective fields, aiming to drive growth and shareholder value.
Read more →-CRL
Feb 18, 2026Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
Charles River Laboratories reported a fourth-quarter revenue of $994.2 million for 2025, reflecting a slight decrease from the previous year. The company experienced a GAAP loss per share of $(5.62) due to significant non-cash impairments. Despite these challenges, Charles River expressed cautious optimism for 2026, anticipating a return to organic revenue growth driven by improved demand trends and strategic initiatives.
Read more →-CRL
Jan 22, 2026Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
Charles River Laboratories will announce its fourth-quarter and full-year 2025 financial results on February 18th, along with guidance for 2026. A conference call is set for the same day at 8:30 a.m. ET, allowing investors to engage directly with the company's leadership. This event reflects the company's commitment to transparency and investor relations.
Read more →-CRL
Jan 21, 2026Charles River Enters Manufacturing Collaboration with Gazi University
Charles River Laboratories has announced a collaboration with Gazi University Faculty of Medicine to enhance gene therapy research. This partnership will focus on providing plasmid DNA for AAV production and efficacy studies, particularly targeting hyperphosphatemic tumoral calcinosis. The collaboration aims to transform innovative concepts into effective therapies for rare diseases.
Read more →-CRL
Jan 13, 2026Charles River Laboratories Provides Business Updates
Charles River Laboratories announced two acquisitions aimed at enhancing its supply chain and testing capabilities. The company plans to acquire K.F. (Cambodia) Ltd. to secure its non-human primate supply and PathoQuest SAS to bolster its biologics testing solutions. Additionally, Dr. Namandjé Bumpus has been appointed as Chief Scientific and Innovation Officer. The company is optimistic about business trends and its 2026 outlook.
Read more →-CRL
Sep 16, 2025CHARLES RIVER LABORATORIES ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION - Michael G. Knell, Corporate Senior Vice President & Chief Accounting Officer, Appointed Interim CFO by the Board of Directors - - Com
Charles River Laboratories announced the resignation of Flavia H. Pease as Chief Financial Officer, effective September 29, 2025. Michael G. Knell, currently the Corporate Senior Vice President and Chief Accounting Officer, will step in as interim CFO while a search for a permanent replacement is conducted. The company reaffirmed its financial guidance for revenue and non-GAAP earnings per share for 2025, indicating confidence in its operational strategies despite the leadership transition.
Read more →-CRL
May 7, 2025▲ +18.7%on this news
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value - Board Approves Appointment of Four New Directors - - Strategic Planning and Capital Alloc
Charles River Laboratories announced a significant governance update, including the appointment of four new directors and a strategic review to enhance long-term shareholder value. This review will be conducted by the newly formed Strategic Planning and Capital Allocation Committee, which aims to evaluate the company’s business prospects. The changes come alongside a Cooperation Agreement with Elliott Investment Management, further illustrating support from the company’s largest investor. These initiatives reflect the company's commitment to adapting to market conditions and optimizing operations.
Read more →-CRL
Feb 14, 2024▲ +11.3%on this news
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance - Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion - - Fourth-Quarter GAAP Earnings
Charles River Laboratories reported its fourth-quarter and full-year 2023 results, revealing a fourth-quarter revenue of $1.01 billion, which is a 7.9% decrease from last year. The company also provided guidance for 2024, expecting some level of constrained client spending to persist. Despite the drop in revenue and margins, the CEO expressed confidence in the company's strategy and adaptability to market changes. Overall, 2023 revenue increased by 3.9% year-over-year, though net income and earnings per share decreased slightly compared to 2022.
Read more →-CRL
Nov 8, 2023Charles River Laboratories Announces Third-Quarter 2023 Results - Third-Quarter Revenue of $1.03 Billion - - Third-Quarter GAAP Earnings per Share of $1.69 and Non-GAAP Earnings per Share of $2.72 - - Updates 2023 Guidan
Charles River Laboratories reported its financial results for the third quarter of 2023, noting a revenue increase to $1.03 billion, attributed to various service segments. While non-GAAP earnings per share rose to $2.72, reflecting a 3.4% growth, GAAP earnings experienced a decline of 10.1% to $1.69 per share. The company anticipates an adjustment in 2023 guidance due to shifts in financial results, indicating a cautious yet positive view on demand trends moving forward. Overall, the financial performance presents a mixed outlook with significant growth in certain areas but challenges in others related to client spending.
Read more →-CRL
Aug 9, 2023Charles River Laboratories Announces Second-Quarter 2023 Results - Second-Quarter Revenue of $1.06 Billion - - Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 - - Updates 2023 Gui
Charles River Laboratories reported its second-quarter results for 2023, revealing a revenue of $1.06 billion, representing an 8.9% increase from the previous year. Organic revenue growth was attributed to the Research Models and Services and Discovery and Safety Assessment segments. However, the company also noted declines in net income and earnings per share, both on a GAAP and non-GAAP basis due to non-operating items and the impact from a recent divestiture. The company is closely monitoring demand trends from biopharmaceutical clients and has updated its full-year guidance, projecting revenue growth to range between 2.5% and 4.5% for 2023.
Read more →-CRL
May 11, 2023▲ +5.1%on this news
Charles River Laboratories Announces First-Quarter 2023 Results - First-Quarter Revenue of $1.03 Billion - - First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 - - Updates 2023 Guidan
Charles River Laboratories reported strong first-quarter results for 2023, with revenue reaching $1.03 billion, a rise of 12.6% from the previous year. GAAP earnings per share increased by 11% to $2.01, while non-GAAP earnings rose by 1.1% to $2.78. Despite robust performance in the Discovery and Safety Assessment segment, challenges in the Manufacturing segment and the divestiture of the Avian Vaccine business negatively impacted overall growth. The company provided updated guidance for 2023, reflecting based on its first-quarter performance and underlying economic conditions.
Read more →-CRL
Feb 22, 2023▼ -10.1%on this news
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance - Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion - - Fourth-Quarter GAAP Earnings
Charles River Laboratories reported strong financial results for the fourth quarter and full year of 2022, with Q4 revenue reaching $1.10 billion, an increase of 21.5% from the previous year. The company's net income and earnings per share also saw significant growth, particularly within its Discovery and Safety Assessment segment. However, challenges such as decreased operating margins in Manufacturing and a DOJ investigation into their non-human primate supply chain could pose risks moving forward. The company remains optimistic about navigating these issues and maintaining solid business fundamentals in 2023.
Read more →-CRL
Nov 2, 2022Charles River Laboratories Announces Third-Quarter 2022 Results - Third-Quarter Revenue of $989.2 Million - - Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 - - Narrows 2022 Reven
Charles River Laboratories Announces Third-Quarter 2022 Results - Third-Quarter Revenue of $989.2 Million - - Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 - - Narrows 2022 Revenue Growth and Earnings Per Share Guidance - - Announces
Read more →-CRL
Aug 3, 2022▼ -9.1%on this news
Charles River Laboratories Announces Second-Quarter 2022 Results - Second-Quarter Revenue of $973.1 Million - - Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 - - Reduces 2022 Gu
Charles River Laboratories Announces Second-Quarter 2022 Results - Second-Quarter Revenue of $973.1 Million - - Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 - - Reduces 2022 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--August 3, 2
Read more →-CRL
May 4, 2022Charles River Laboratories Announces First-Quarter 2022 Results - First-Quarter Revenue of $913.9 Million - - First-Quarter GAAP Earnings per Share of $1.81 and Non-GAAP Earnings per Share of $2.75 - - Updates 2022 Guida
Charles River Laboratories Announces First-Quarter 2022 Results - First-Quarter Revenue of $913.9 Million - - First-Quarter GAAP Earnings per Share of $1.81 and Non-GAAP Earnings per Share of $2.75 - - Updates 2022 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--May 4, 2022--C
Read more →-CRL
Feb 16, 2022Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results - Fourth-Quarter Revenue of $905.1 Million and Full-Year Revenue of $3.54 Billion - - Fourth-Quarter GAAP Earnings per Share of $2.67 and Non
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results - Fourth-Quarter Revenue of $905.1 Million and Full-Year Revenue of $3.54 Billion - - Fourth-Quarter GAAP Earnings per Share of $2.67 and Non-GAAP Earnings per Share of $2.49 - - Full-Year GAAP Earn
Read more →-CRL
Jan 11, 2022▲ +7.1%on this news
aex991xcrljpm2022present EVERY STEP OF THE WAY 2022 Charles River Laboratories International, Inc. JP Morgan 40th Annual Healthcare Conference James C. Foster Chairman, President & Chief Executive Officer Charles River L
EVERY STEP OF THE WAY 2022 Charles River Laboratories International, Inc. JP Morgan 40th Annual Healthcare Conference James C. Foster Chairman, President & Chief Executive Officer Charles River Laboratories January 11, 2022 EVERY STEP OF THE WAY Safe Harbor Statement Caution Con
Read more →-CRL
Nov 3, 2021▼ -10.2%on this news
Charles River Laboratories Announces Third-Quarter 2021 Results - Third-Quarter Revenue of $895.9 Million - - Third-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.70 - - Updates 2021 Guida
Charles River Laboratories Announces Third-Quarter 2021 Results - Third-Quarter Revenue of $895.9 Million - - Third-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.70 - - Updates 2021 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--November 3, 20
Read more →-CRL
Aug 4, 2021Charles River Laboratories Announces Second-Quarter 2021 Results Second-Quarter Revenue of $914.6 Million Second-Quarter GAAP Earnings per Share of $1.72 and Non-GAAP Earnings per Share of $2.61 Increases 2021 Guidance W
Charles River Laboratories Announces Second-Quarter 2021 Results Second-Quarter Revenue of $914.6 Million Second-Quarter GAAP Earnings per Share of $1.72 and Non-GAAP Earnings per Share of $2.61 Increases 2021 Guidance WILMINGTON, Mass.--(BUSINESS WIRE)--August 4, 2021--Charl
Read more →-CRL
May 18, 2021CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the " Agreement ") is hereby entered into as of
RIVER LABORATORIES INTERNATIONAL, INC. AND RESTATED EMPLOYMENT AGREEMENT AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the "Agreement") is hereby entered into as of May 18, 2021 by and between Charles River Laboratories International, Inc., a Delaware corporation (the "Company"),
Read more →-CRL
May 4, 2021Charles River Laboratories Announces First-Quarter 2021 Results - First-Quarter Revenue of $824.6 Million - - First-Quarter GAAP Earnings per Share of $1.20 and Non-GAAP Earnings per Share of $2.53 - - Updates 2021 Guida
Charles River Laboratories Announces First-Quarter 2021 Results - First-Quarter Revenue of $824.6 Million - - First-Quarter GAAP Earnings per Share of $1.20 and Non-GAAP Earnings per Share of $2.53 - - Updates 2021 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--May 4, 2021--C
Read more →-CRL
Mar 8, 2021CHARLES RIVER LABORATORIES ANNOUNCES PLANNED OFFERING OF $1
RIVER LABORATORIES ANNOUNCES PLANNED OFFERING OF $1 BILLION OF SENIOR NOTES WILMINGTON, Mass., March 8, 2021 - Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $1 billion aggregate principal amount of senior notes due 2029 an
Read more →-CRL
Feb 17, 2021Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance - Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion - - Fourth-Quarter GAAP Earnings
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance - Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion - - Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.
Read more →-CRL
Feb 17, 2021CHARLES RIVER LABORATORIES TO ACQUIRE COGNATE BIOSERVICES TO CREATE A PREMIER SCIENTIFIC PARTNER FOR CELL AND GENE THERAPY DEVELOPMENT - Significantly Expands Charles River's Scientific Capabilities in the H
RIVER LABORATORIES TO ACQUIRE COGNATE BIOSERVICES TO CREATE A PREMIER SCIENTIFIC PARTNER FOR CELL AND GENE THERAPY DEVELOPMENT Significantly Expands Charles River's Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector - Combines Cognate's Comprehensive Ce
Read more →-CRL
Oct 29, 2020Charles River Laboratories Announces Third-Quarter 2020 Results - Third-Quarter Revenue of $743.3 Million - - Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 - - Increases 2020 Gui
Charles River Laboratories Announces Third-Quarter 2020 Results - Third-Quarter Revenue of $743.3 Million - - Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 - - Increases 2020 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--October 29,
Read more →-CRL
Aug 5, 2020Charles River Laboratories Announces Second-Quarter 2020 Results - Second-Quarter Revenue of $682.6 Million - - Second-Quarter GAAP Earnings per Share of $1.34 and Non-GAAP Earnings per Share of $1.58 - - Increases 2020
Charles River Laboratories Announces Second-Quarter 2020 Results - Second-Quarter Revenue of $682.6 Million - - Second-Quarter GAAP Earnings per Share of $1.34 and Non-GAAP Earnings per Share of $1.58 - - Increases 2020 Guidance - - Announces Proposed Acquisition of Cellero i
Read more →-CRL
May 7, 2020Charles River Laboratories Announces First-Quarter 2020 Results - First-Quarter Revenue of $707.1 Million - - First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $1.84 - - Revises 2020 Guida
Charles River Laboratories Announces First-Quarter 2020 Results - First-Quarter Revenue of $707.1 Million - - First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $1.84 - - Revises 2020 Guidance Due to COVID-19 Impact - WILMINGTON, Mass.--(BUSINES
Read more →-CRL
Feb 11, 2020Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance - Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion - - Fourth-Quarter GAAP Earnings
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance - Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion - - Fourth-Quarter GAAP Earnings per Share of $1.61 and Non-GAAP Earnings per Share of $2.
Read more →-CRL
Nov 6, 2019Charles River Laboratories Announces Third-Quarter 2019 Results - Third-Quarter Revenue of $668.0 Million - - Third-Quarter GAAP Earnings per Share of $1.46 and Non-GAAP Earnings per Share of $1.69 - - Updates 2019 Guida
Charles River Laboratories Announces Third-Quarter 2019 Results - Third-Quarter Revenue of $668.0 Million - - Third-Quarter GAAP Earnings per Share of $1.46 and Non-GAAP Earnings per Share of $1.69 - - Updates 2019 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--November 6, 20
Read more →-CRL
Oct 21, 2019Excerpts from the Preliminary Offering Memorandum dated
Excerpts from the Preliminary Offering Memorandum dated October 21, 2019 Recent developments - Preliminary and unaudited estimates of the Company's selected third quarter 2019 results Set forth below are preliminary estimates of unaudited selected financial information for the
Read more →-CRL
Jul 31, 2019Charles River Laboratories Announces Second-Quarter 2019 Results - Second-Quarter Revenue of $657.6 Million - - Second-Quarter GAAP Earnings per Share of $0.88 and Non-GAAP Earnings per Share of $1.63 - - Updates 2019 Gu
Charles River Laboratories Announces Second-Quarter 2019 Results - Second-Quarter Revenue of $657.6 Million - - Second-Quarter GAAP Earnings per Share of $0.88 and Non-GAAP Earnings per Share of $1.63 - - Updates 2019 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--July 31, 20
Read more →-CRL
May 7, 2019Charles River Laboratories Announces First-Quarter 2019 Results - First-Quarter Revenue of $604.6 Million - - First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share of $1.40 - - Reaffirms 2019 Gui
River Laboratories Announces First-Quarter 2019 Results First-Quarter Revenue of $604.6 Million - First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Reaffirms 2019 Guidance Including Citoxlab - WILMINGTON, Mass.--(BUSINESS WIRE)--May 7, 2019--Charles Riv
Read more →-CRL
Feb 13, 2019CHARLES RIVER LABORATORIES SIGNS BINDING OFFER TO ACQUIRE CITOXLAB Further Strengthens Charles River s Position as the Leading Global Early-Stage CRO Transaction Expected to be Accretive to Non-GAAP EPS by A
CHARLES RIVER LABORATORIES SIGNS BINDING OFFER Further Strengthens Charles River s Position as the Leading Global Early-Stage CRO Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.15 in 2019 and At Least $0.35 in 2020 WILMINGTON, MA, February 13, 2019
Read more →-CRL
Feb 13, 2019Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance - Fourth-Quarter Revenue of $601.5 Million and Full-Year Revenue of $2.27 Billion - - Fourth-Quarter GAAP Earnings
River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance Fourth-Quarter Revenue of $601.5 Million and Full-Year Revenue of $2.27 Fourth-Quarter GAAP Earnings per Share of $1.21 and Non-GAAP Earnings per Share of $1.49 - Full-Year GAAP
Read more →-CRL
Nov 7, 2018Charles River Laboratories Announces Third-Quarter 2018 Results - Third-Quarter Revenue of $585.3 Million - - Third-Quarter GAAP Earnings per Share of $1.22 and Non-GAAP Earnings per Share of $1.53 - - Updates 2018 Guida
River Laboratories Announces Third-Quarter 2018 Results Third-Quarter Revenue of $585.3 Million - Third-Quarter GAAP Earnings per Share of $1.22 and Non-GAAP Earnings per WILMINGTON, Mass.--(BUSINESS WIRE)--November 7, 2018--Charles River Laboratories International, Inc. (NYS
Read more →-CRL
Aug 8, 2018Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations - Second-Quarter Revenue of $585.3 Million - - Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share o
River Laboratories Announces Second-Quarter 2018 Results from Continuing Second-Quarter Revenue of $585.3 Million - Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $1.62 - Increases 2018 Revenue Growth and Earnings per Share Guidance - WILM
Read more →-CRL
May 10, 2018Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations - First-Quarter Revenue of $494.0 Million - - First-Quarter GAAP Earnings per Share of $1.08 and Non-GAAP Earnings per Share of $
River Laboratories Announces First-Quarter 2018 Results from Continuing First-Quarter Revenue of $494.0 Million - First-Quarter GAAP Earnings per Share of $1.08 and Non-GAAP Earnings per WILMINGTON, Mass.--(BUSINESS WIRE)--May 10, 2018--Charles River Laboratories Internationa
Read more →-CRL
Mar 26, 2018CHARLES RIVER LABORATORIES ANNOUNCES REFINANCING OF CREDIT FACILITIES AND OFFERING OF $500
RIVER LABORATORIES ANNOUNCES REFINANCING OF CREDIT FACILITIES AND OFFERING OF $500 MILLION OF SENIOR NOTES WILMINGTON, MA, March 26, 2018 - Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has refinanced its existing $1.0 billion of revolving
Read more →-CRL
Feb 13, 2018CHARLES RIVER LABORATORIES TO ACQUIRE MPI RESEARCH - Enhances Charles River's Position as a Leading Global Early-Stage CRO - - Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.25 in 2
RIVER LABORATORIES TO ACQUIRE MPI RESEARCH Enhances Charles River's Position as a Leading Global Early-Stage CRO - Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.25 in 2018 and Approximately $0.60 in 2019 - WILMINGTON, MA, February 13, 2018 - Charle
Read more →-CRL
Feb 13, 2018Charles River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 Guidance - Fourth-Quarter Revenue of $478.5 Million and Full-Year 2017 Revenue of $1.86 Billion
River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 Guidance Fourth-Quarter Revenue of $478.5 Million and Full-Year 2017 Revenue of Fourth-Quarter GAAP Loss per Share of $0.63 and Non-GAAP Earnings per Full-Year
Read more →-CRL
Nov 9, 2017Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations - Third-Quarter Revenue of $464.2 Million - - Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30 - - Updates 2017 Guidance
River Laboratories Announces Third-Quarter 2017 Results from Continuing Third-Quarter Revenue of $464.2 Million - Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30 - WILMINGTON, Mass.--(BUSINESS WIRE)--November 9, 2017--Charles River Laboratories International, Inc. (
Read more →-CRL
Aug 9, 2017Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations - Second-Quarter Revenue of $469.1 Million - - Second-Quarter GAAP EPS of $1.12 and Non-GAAP EPS of $1.29 - - Updates 2017 Guida
Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations - Second-Quarter Revenue of $469.1 Million - - Second-Quarter GAAP EPS of $1.12 and Non-GAAP EPS of $1.29 - - Updates 2017 Guidance - WILMINGTON, Mass.--(BUSINESS WIRE)--August 9, 2017
Read more →-CRL
May 10, 2017Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations - First-Quarter Revenue of $445.8 Million - - First-Quarter GAAP EPS of $0.97 and Non-GAAP EPS of $1.29 - - Updates 2017 Guidance
River Laboratories Announces First-Quarter 2017 Results from Continuing First-Quarter Revenue of $445.8 Million - First-Quarter GAAP EPS of $0.97 and Non-GAAP EPS of $1.29 - WILMINGTON, Mass.--(BUSINESS WIRE)--May 10, 2017--Charles River Laboratories International, Inc. (NYSE
Read more →-CRL
Feb 14, 2017Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance - Fourth-Quarter Revenue of $466.8 Million and Full-Year 2016 Revenue of $1.68 Billion
River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance Fourth-Quarter Revenue of $466.8 Million and Full-Year 2016 Revenue of Fourth-Quarter GAAP Earnings per Share of $0.93 and Non-GAAP Earnings per Share
Read more →-CRL
Nov 2, 2016Charles River Laboratories Announces Third-Quarter 2016 Results from Continuing Operations - Third-Quarter Revenue of $425.7 Million - - Third-Quarter GAAP Earnings per Share of $0.78 and Non-GAAP Earnings per Share of $
River Laboratories Announces Third-Quarter 2016 Results from Continuing Third-Quarter Revenue of $425.7 Million - Third-Quarter GAAP Earnings per Share of $0.78 Non-GAAP Earnings per Share of $1.18 - WILMINGTON, Mass.--(BUSINESS WIRE)--November 2, 2016--Charles River Laborat
Read more →-CRL
Aug 3, 2016Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations - Second-Quarter Revenue of $434.1 Million - - Second-Quarter GAAP Earnings per Share of $0.73 and Non-GAAP Earnings per Share o
River Laboratories Announces Second-Quarter 2016 Results from Continuing Second-Quarter Revenue of $434.1 Million - Second-Quarter GAAP Earnings per Share of $0.73 Non-GAAP Earnings per Share of $1.20 - WILMINGTON, Mass.--(BUSINESS WIRE)--August 3, 2016--Charles River Labora
Read more →-CRL
May 4, 2016Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations - First-Quarter Revenue of $354.9 Million - - First-Quarter GAAP Earnings per Share of $0.78 and Non-GAAP Earnings per Share of $
River Laboratories Announces First-Quarter 2016 Results from Continuing First-Quarter Revenue of $354.9 Million - First-Quarter GAAP Earnings per Share of $0.78 Non-GAAP Earnings per Share of $0.98 - WILMINGTON, Mass.--(BUSINESS WIRE)--May 4, 2016--Charles River Laboratories
Read more →Competitive Position
How CRL ranks across every disease it competes inCompetitive Position is a premium feature
See how CRL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial